Thrombocytopenia is a common bleeding disorder with many causes, the most common being idiopathic thrombocytopenic purpura (ITP), a common hematologic condition characterized by a significant reduction in platelets and bleeding from the skin, mucous membranes, and even organs. It is characterized by peripheral thrombocytopenia, shortened platelet lifespan, normal or increased bone marrow megakaryocytes, and impaired maturation. According to the clinical manifestations, age of onset, duration of thrombocytopenia and treatment effect, it is divided into acute type and chronic type. Acute type is mostly seen in children and is often self-limiting, while chronic type is more likely to occur in young women. At present, the treatment is mostly based on immunosuppressive therapy. But in clinical work we can often encounter this kind of patients, must pursue the platelet count to improve to the level of normal people, this attitude is not desirable. The main function of platelets is to stop bleeding, and the main problem of ITP is also bleeding. We can easily understand that as long as the patient does not bleed, it is not enough. Why must the platelets be raised to normal? Some patients may ask why not if it can be raised to a normal level. There is a problem of inconsistent perception between the doctor and the patient. Which perception is correct? Undoubtedly, the doctor is right. It is also wrong if a certain doctor must raise your platelets to normal levels and keep increasing the hormone dose or applying drugs like prednisone and Medrol for a long time in high doses. It is understandable that patients ask for raising their platelets to normal levels. However, we should recognize that for some patients, this may require an increased dose of prednisone or a larger dose over time to maintain, with resulting side effects that we cannot accept. Such as infections due to the patient’s reduced resistance, edema due to the long-term application of corticosteroids, the appearance of full moon faces and buffalo waists, facial acne, and even osteoporosis and femoral head necrosis, and all of these side effects are far more harmful than platelet reduction. This is typical of the dangers associated with overmedication. ITP is an autoimmune benign disease for which there is no complete cure, and the goal of ITP treatment is to raise the patient’s platelet count to a safe range to prevent severe bleeding and reduce the death rate, not to bring the platelet count to a normal range. Therefore, in clinical practice, if the platelet count is greater than 30×109/L, there is no bleeding manifestation, and the patient is not engaged in work or activities that increase the risk of bleeding, the patient may not be treated, but should be followed up and observed. If the platelet count is lower than 30×109/L, or if there are bleeding symptoms, or if the patient is older, has had the disease for a long time, or if there are coagulation disorders, platelet function defects, or if there are factors such as hypertension, infection, trauma, or if the patient is taking anti-platelet aggregation drugs, then therapeutic intervention is required. Therefore, for patients who do not need therapeutic intervention, overtreatment will not only fail to control the disease, but also increase the incidence of complications and even endanger the patient’s life. Therefore, for patients who need treatment must be considered in the context of bleeding risk, efficacy, side effects, and patient compliance, and the pros and cons must be weighed before selecting an appropriate individualized treatment method, and the side effects of the drug must be minimized without affecting the efficacy. The goal of ITP treatment is not to achieve a normal platelet count, but to raise it to a safe level, i.e., (30-50) × 109/L, and not to treat it excessively. It is important not to overtreat. So what are the criteria for the efficacy of ITP treatment? There should be 3 levels, first, the platelets are normal, which is the best; second, the platelets can not reach the normal requirements, but can also maintain about 50,000, will not affect the patient’s quality of life, which is also acceptable; third, the platelets are significantly low, at about 10,000, may partially limit the patient’s life, such as can not engage in strenuous exercise, etc.. This last point is often a nagging concern for patients. The problem is that such patients are generally taking 2-4 tablets of prednisone on a continuous basis. Increasing the dose may raise the platelets, but they do not realize that the resulting side effects are more harmful, and it is then the doctor’s responsibility to explain the situation to the patient and help prompt them to understand the purpose of the treatment, rather than accommodating the patient by raising the hormone dose indefinitely to achieve the purpose of raising the platelets. The American Society of Hematology, the British Society of Hematology Standardization Committee, and the Chinese expert consensus on ITP treatment all clearly mention that the minimum treatment goal for ITP is no bleeding, not long-term high-dose hormone application. This is something that I hope patients will fully recognize and understand, and to recognize the dangers of overmedication. Most children with ITP have a history of viral infection before the disease, so they need to actively prevent colds and flu, as well as cautious vaccination to avoid triggering and aggravating bleeding. Close observation of bleeding in general helps to understand the activity of the disease so that it can be treated promptly. Avoid trauma and absolute bed rest is required for severe bleeding. In chronic patients, according to the actual situation, participate in exercise, avoid collision, keep a happy mood, and avoid spicy and hard food. Pay attention to skin hygiene, avoid scratching the skin to cause infection, avoid taking aspirin and all drugs that affect platelet coagulation, so as not to aggravate the bleeding. Normally, you can use peanut shells to make water as tea.